Assembly Biosciences presents positive Phase 1b data for two herpes treatments at ESCMID 2026.

Assembly Biosciences announced positive Phase 1b clinical data for two investigational herpes treatments, ABI-5366 and ABI-1179, which will be presented at the ESCMID 2026 conference. ABI-5366 data includes results from a monthly dosing cohort and was selected for an oral presentation, highlighting its potential as a long-acting oral treatment for recurrent genital herpes. ABI-1179's Phase 1b data was accepted as a late-breaker poster presentation, emphasizing its promise as another long-acting therapeutic option. Both drugs are licensed to Gilead Sciences, which will handle further development and commercialization.